In December 2014, another pricey agent to treat hepatitis C virus (HCV) infection entered the market. Viekira Pak (AbbVie Inc.; North Chicago, IL), a combination of ombitasvir, paritaprevir, and ritonavir fixed-dose combination tablets co-packaged with dasabuvir tablets, is approved to treat patients with chronic HCV genotype 1 infection, including those with cirrhosis.
Over the past 15 months, in addition to Viekira Pak, the Food and Drug Administration (FDA) approved 3 other agents to treat chronic HCV infection. The FDA approved Olysio (simeprevir; Janssen Pharmaceuticals, Raritan, NJ) in November 2013, Sovaldi (sofosbuvir; Gilead Sciences, Foster City, CA) in December 2013, and Harvoni (ledipasvir plus sofosbuvir; Gilead Sciences, Foster City, CA) in October 2014. Compared with combination therapy with pegylated interferon plus ribavirin, the newest agents deliver improved response rates with fewer side effects. They also come with hefty price tags, forcing insurers and state Medicaid agencies to negotiate with manufacturers to secure discounts to reduce costs.
Hayes has up-to-date resources payers can use to assess the impact of Viekira Pak on patient health outcomes. Our latest report, entitled Triple Direct-Acting Antiviral (DAA) Regimen for Hepatitis C Virus (HCV) (Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir), reviews the evidence for Viekira Pak and assigns a Hayes Rating to this new agent. Subscribers can access this report through our Knowledge Center. Hayes also has published 2 other health technology assessments and assigned Hayes Ratings to Olysio and Harvoni:
- Second-Wave Direct-Acting Antivirals for Hepatitis C: Simeprevir
- Second-Wave Direct-Acting Antivirals for Hepatitis C: Sofosbuvir and Ledipasvir
Both of these reports are available to Hayes subscribers through the Knowledge Center. If you aren’t a Hayes customer, contact us to purchase any of these reports individually.